Challenges with Trump’s Vaccine Executive Order
Health experts have criticized an executive order from President Donald Trump that changes childhood vaccinations in the U.S. The order requires the separation of combination vaccines like the measles, mumps, and rubella (MMR) shot into individual injections, with vaccinations spaced out whenever possible. This move faces financial and logistical obstacles for parents, healthcare providers, and vaccine manufacturers.
Impact on Drug Manufacturers
To implement the order, drug manufacturers must restart production of single vaccines not widely used in the U.S. for decades. They would also need new facilities to produce millions of additional doses. Currently, the U.S. relies on combination vaccines, which studies show help ensure children are fully vaccinated against diseases before attending school.
Healthcare Providers and Parents
Unbundling the MMR vaccine adds more doctor visits for parents, causing inconvenience and potentially increasing costs for syringes and supplies. Pediatricians may face extra workload, and missed appointments could decrease vaccination rates. Experts like Dr. Anna Durbin from Johns Hopkins Bloomberg School of Public Health argue there’s no scientific reason for the policy change, calling it bad public health policy.
Regulatory and Manufacturing Hurdles
Under the order, federal officials have 90 days to devise plans to separate the MMR shot. However, developing and licensing individual vaccines could take years and require millions in investment. No single vaccines for measles, mumps, or rubella currently exist in the U.S., and new manufacturing plants take about five years to build and approve.
Dr. Jesse Goodman, a former FDA vaccine chief, emphasized the need for large studies to ensure new individual shots elicit immune responses similar to current vaccines. The FDA also must review and license each vaccine separately, an unprecedented process.
Commercial Perspective and Legal Implications
Vaccine companies like Merck and GSK support the safety and effectiveness of their combination products and have no plans to unbundle their shots. The order lacks legal force, as neither the White House nor FDA can mandate companies to create new vaccines. States, which have authority over school vaccination requirements, likely won’t adopt the changes.
Dr. Paul Offit from Children’s Hospital of Philadelphia sees no business incentive for companies to pursue individual vaccines, noting they’d compete with their existing products. Implementing Trump’s order remains unlikely without legal and commercial support.